From Bench to Bedside: Targeted mRNA Delivery Achieved with Sustainable, Lyophilizable Nanoparticles

Post-pandemic, mRNA technology has evolved from laboratory curiosity to global sensation, becoming one of biotechnology's brightest stars. Yet behind this revolutionary approach lies a set of persistent challenges: current delivery systems—viral vectors and lipid nanoparticles (LNPs)—face manufacturing complexity, stringent storage requirements, safety concerns, and crowded intellectual property landscapes. Perhaps most critically, conventional LNPs rely on petrochemical-derived synthetic lipids, conflicting with the growing demand for sustainable pharmaceutical solutions. Against this backdrop, researchers from Purdue University have published breakthrough findings in the Proceedings of the National Academy of Sciences (PNAS), introducing their layer-by-layer elastin-like polypeptide nucleic acid nanoparticle (LENN) system—a technology that not only overcomes existing limitations but charts a greener path forward for mRNA delivery.

Biorenewable Materials: Solving the Sustainability Challenge

At its core, the LENN system's innovation lies in its materials and design philosophy. While traditional LNPs depend on petroleum-derived synthetic lipids, LENN employs biorenewable materials based on human tropoelastin sequences. This elegantly engineered system comprises three precisely designed components: an outer layer of elastin-like polypeptides (ELPs), a middle layer of β-cyclodextrin-polyarginine conjugates (CD-PLR10), and an inner core of mRNA cargo. The ELPs can be engineered for targeted delivery (such as to epidermal growth factor receptor, EGFR), while CD-PLR10 self-assembles with ELPs through unique host-guest interactions and simultaneously condenses the negatively charged mRNA through ionic binding.

"This design solves not just delivery efficiency challenges but, more importantly, utilizes biomanufacturable materials that dramatically reduce production complexity and environmental footprint," explains Professor David H. Thompson, the study's lead investigator. "Our LENN system can be prepared under standard laboratory conditions without complex microfluidic equipment, paving the way for scalable manufacturing."

Breakthrough Performance: Stability and Targeting in Perfect Harmony

The research data reveals LENN's exceptional performance across multiple critical metrics. Through simple batch mixing methods, the system forms uniform particles ranging from 30-130 nm—a size ideal for cellular uptake and in vivo distribution. More significantly, LENN maintains nearly 80% encapsulation efficiency after heparin challenge (simulating competitive binding in physiological environments), substantially outperforming conventional polyion complexes. This stability ensures mRNA remains protected until it reaches target cells.

Targeting capability represents another LENN strength. Using T24 bladder cancer cells as a model, the research team demonstrated that EGF-decorated LENN specifically recognizes and binds to EGFR-overexpressing tumor cells, efficiently entering via clathrin-mediated endocytosis. When excess free EGF was added to block receptors, cellular uptake dramatically decreased, confirming targeting specificity. In live mouse experiments, targeted LENN accumulated 2.3 times more in tumor tissues than non-targeted controls, showcasing remarkable in vivo targeting ability.

Game-Changing Advantage: Lyophilization Stability Redefines mRNA Storage

Perhaps LENN's most revolutionary breakthrough is its tolerance to lyophilization (freeze-drying). Conventional LNP-mRNA complexes require storage at -70°C, creating complex cold chain dependencies that multiply costs and limit global accessibility. In stark contrast, LENN systems, when formulated with 10% glycerol as a cryoprotectant, remain stable as lyophilized powders at -20°C for at least three days, retaining full biological activity upon rehydration.

"This characteristic could fundamentally transform how mRNA therapeutics are distributed," notes Dr. Saloni Darji, the paper's first author. "Imagine clinics in remote regions where healthcare workers simply rehydrate freeze-dried powder to immediately use potent mRNA medicines, eliminating dependence on complex cold chain infrastructure. This has profound implications for global health equity."

Mechanistic Insights: Lipidomics Reveals New Endocytosis Perspectives

Beyond practical advantages, the study delves deeply into LENN's cellular internalization mechanisms. Through lipidomic analysis, the research team discovered for the first time that upregulated phospholipid biosynthesis plays a crucial role in nanoparticle internalization and endosomal escape. Cells treated with targeted LENN showed significant changes in phosphatidylserine (PS) and phosphatidylethanolamine (PE) levels—lipids involved in membrane curvature and endocytic vesicle formation—providing new perspectives on nanocarrier-cell interactions.

The research confirms LENN primarily enters cells via clathrin-mediated endocytosis, a pathway essential for EGFR-targeted delivery. Through specific inhibitor experiments, when chlorpromazine (a clathrin inhibitor) was used, cellular mRNA uptake decreased by 95%, while caveolae and macropinocytosis inhibitors showed relatively minor effects. This finding not only explains LENN's efficient delivery mechanism but also provides theoretical foundations for designing more precise targeted systems in the future.

Commercialization Pathway: From Lab Bench to Market Shelf

LENN technology holds substantial commercialization potential. Unlike LNPs requiring complex microfluidic mixing equipment, LENN can be prepared through simple batch mixing methods, significantly lowering production barriers. Material-wise, ELPs can be produced at scale through microbial fermentation, eliminating dependence on petrochemical feedstocks and aligning with green chemistry principles. Both cyclodextrin and arginine are FDA-approved excipients with excellent safety profiles, accelerating regulatory pathways.

The technology has already been patented by Purdue University, and the research team is collaborating with pharmaceutical companies on preclinical evaluation. While the journey from laboratory to clinic remains challenging, LENN's platform flexibility allows extension beyond mRNA delivery to siRNA, plasmid DNA, and other nucleic acid therapeutics, offering new treatment options for cancer, genetic disorders, and infectious diseases.

"We're not trying to completely replace LNPs but rather provide a complementary solution," emphasizes Professor Thompson. "In certain applications—such as when targeted delivery, long-term storage, or environmental sustainability are priorities—LENN may emerge as the superior choice. A diverse portfolio of delivery platforms will collectively advance gene therapy."

Industry Impact: Potential to Reshape the mRNA Ecosystem

LENN technology's emergence carries profound implications for the entire mRNA therapeutics ecosystem. First, it offers new approaches to solving the "last mile" delivery problem, particularly for solid tumor targeting. Second, its lyophilization stability could disrupt existing supply chain models, reducing drug costs and improving accessibility. Most significantly, LENN's biorenewable nature aligns with the pharmaceutical industry's shift toward sustainability, resonating with ESG (Environmental, Social, and Governance) investment principles.

Industry analysts predict that as the technology matures, the LENN platform may first achieve breakthroughs in localized delivery applications (such as intravesical treatment for bladder cancer) before expanding to systemic administration. Compared to existing LNP technologies, LENN operates in a more open patent landscape, offering companies opportunities to navigate around crowded IP territories.

Future Outlook: Continuous Optimization and Application Expansion

The research team has already mapped out next steps for LENN technology optimization. First, employing microfluidics to further control particle size and uniformity; second, exploring different targeting ligands to expand disease applications; and third, deepening lyophilization research to extend room-temperature storage duration. Concurrently, the team is collaborating with clinicians to design mRNA therapeutic strategies for bladder cancer, with the first human trials expected within the next two years.

"The future of gene therapy lies not in a single 'perfect' vector but in having multiple tools adaptable to different needs," summarizes Dr. Darji. "The LENN system represents a new philosophy: leveraging nature-designed proteins combined with precise engineering principles to create delivery platforms that are both highly effective and sustainable. This isn't just a technological breakthrough—it's a reimagining of biomaterial design philosophy."

As one industry expert aptly noted: "In the post-pandemic era of mRNA therapeutics, we're no longer just asking 'does it work?' but 'how can it work better?' LENN technology offers not just solutions, but possibilities." As research deepens and industry partnerships advance, this delivery system—inspired by human elastin—may indeed open a greener, more precise, and more accessible new era for gene therapy.